Thank you, Mark. I would like to highlight that in our financials, the cash, cash equivalents A restricted cash position of Selective, excluding Calyxt, as of September 30, 2023, was $72,000,000 compared to $95,000,000 as of December 31, 2022. This $23,000,000 difference mainly reflects $79,000,000 of cash out, which includes $23,000,000 for R and D, dollars 12,000,000 for SG and A, dollars 32,000,000 for staff costs, $8,000,000 for rent and taxes, dollars 4,000,000 of reimbursement of the PGE loan and $2,000,000 unfavorable impact on foreign exchange, partially offset by a $23,000,000 net cash inflow from a capital raise closed in February and a $21,000,000 net cash inflow from the European Investment Bank loan. A $6,000,000 of net cash received from the research tax credit refinancing, A $1,000,000 cash inflow related to the grants and refundable advance from BPI, dollars 3,000,000 of financial investments, capital gain and interest and $1,000,000 reimbursement of social charges paid on stock options and a $2,000,000 net cash inflow from licenses and other cash receipts. With cash and cash equivalents of $67,400,000 as of September 30, 2023 and the $105,000,000 from the AstraZeneca agreement, the company believes that we have sufficient resources to continue operating for at least 12 months following the consolidated financial statements publication.